Top Markets
#1 Black Phoenix Black Phoenix +354.71%
#2 Glidr Glidr +84.34%
#3 OpenEden OpenEden +71.47%
#4 Gold Park Gold Park +68.84%
#5 Akedo Akedo +55.26%
#6 BasedHype BasedHype +26.51%
#7 Cryptopia Cryptopia +21.54%
#8 Humanity Humanity +20.22%
#9 Avantis Avantis +19.35%
#10 Ether.fi Ether.fi +17.25%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Classificação em ações #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Preço da ação
$0.00204105
Valor de mercado
$138.92K
Variação (1 dia)
5.63%
Variação (1 ano)
-60.44%
País
GB
Negociar Solvonis Therapeutics plc (SVNS)

Categoria

Industrials
Receita da Solvonis Therapeutics plc (SVNS)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Solvonis Therapeutics plc, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Solvonis Therapeutics plc de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Lam Research Corp. R Lam Research Corp. R
Lam Research Corp. R
LAR0.DE
 - -
US
Siemens AG Siemens AG
Siemens AG
SIE.DE
 $94.53B -
DE
Schneider Electric S.E. Schneider Electric S.E.
Schneider Electric S.E.
SU.PA
 - -
FR
Siemens Energy AG Siemens Energy AG
Siemens Energy AG
ENR.DE
 - -
DE
Parker-Hannifin Corporation Parker-Hannifin Corporation
Parker-Hannifin Corporation
PH.US
 $21.50B -
US